The underlying biochemical cause of Multiple Sclerosis is the demyelination of neurons.

Myelin is an insulating sheath that surrounds neurons, and is critical for ensuring the transmission of electrical nerve impulses. For unknown reasons, myelin breaks down in the central nervous system of Multiple Sclerosis patients, leading to compromised motor function, resulting in the debilitating symptoms of the disease.

Myelin is largely composed of plasmalogen phospholipids, therefore making Multiple Sclerosis a prime target for therapeutic plasmalogen restoration.
Our pre-clinical work in an in vivo animal model of Multiple Sclerosis demonstrated that plasmalogens are reduced in the brains and plasma of affected animals. Our lead plasmalogen restoration compound for Multiple Sclerosis is a synthetic drug made from individual synthetic myelin components and is directly converted by the body into an active component of myelin. We have shown that treatment with our plasmalogen restoration drug increases plasmalogen levels in the brain, and protects against demyelination in animal models.

We are currently in the process of completing additional preclinical studies required for an FDA IND application for testing in humans.

Publications

- Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer’s Disease. Chapter from the book Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets, Publisher: InTech, Chapters published September 12,2011
- Metabolic dysfunctions in multiple sclerosis: Implications as to causation, early detection, and treatment, a case control study. BMC Neurology 15(1):154. August 2015